Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825039 | 0.85 | EGFR (0.54) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL10993215 | 0.84 | EGFR (0.60) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL6789607 | 0.82 | EGFR (0.58) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL6789611 | 0.82 | EGFR (0.58) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL6932492 | 0.81 | CA1 (0.53) | EGFRERBB2CA2CA1MMP1 | |
| SCHEMBL10420808 | 0.81 | EGFR (0.68) | EGFRERBB2PTGS2PTGS1CA2 | |
| SCHEMBL5174597 | 0.81 | EGFR (0.54) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL3928657 | 0.81 | CA1 (0.67) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL11164400 | 0.81 | EGFR (0.61) | EGFRERBB2KDM4EPTGS2PTGS1 | |
| SCHEMBL28399551 | 0.81 | EGFR (0.57) | EGFRERBB2KDM4EPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5726158-A | INHIBITORS OF HUMAN LEUKOCYTE ELASTASE USEFUL IN TREATING TISSUE DEGENERATIVE DISEASES; TRIFLUOROMETHYL KETONE SUBSTITUTED DI-, TRI-, AND TETRA-PEPTIDE DERIVATIVES | ZENECA INC. (US) | 1998-03-10 | — | — | US | claimed |
| EP-0189305-B1 | PEPTIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1992-07-29 | — | — | EP | claimed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | claimed |
| CN-112218858-B | 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-06-18 | — | — | CN | disclosed |
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2023-04-13 | — | — | US | disclosed |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | MEDICINSK FORSKNING (SE) | 2021-02-25 | — | — | US | disclosed |
| EP-3781554-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | Thomas Helledays stiftelse för medicinsk forskning (SE) | 2021-02-24 | — | — | EP | disclosed |
| CN-112218858-A | 2, 6-diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019201991-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2019-10-24 | — | — | WO | disclosed |
| EP-0757682-B1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-1993021210-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-5194588-A | Inhibitors of human leukocyte elastase, di-, tri- and tetra-peptides | ICI AMERICAS INC. (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0189305-B1 | PEPTIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-5055450-A | Di-, tri- and tetrapeptides as inhibitors of human leukocyte elastase | ICI AMERICAS INC. (US) | 1991-10-08 | — | — | US | disclosed |
| US-4954513-A | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4910190-A | Containing a nitrogen containing heterocycle ring structure | ICI AMERICAS INC. (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0276101-A2 | Substituted peptide derivatives | ICI AMERICAS INC. (US) | 1988-07-27 | — | — | EP | disclosed |
| CN-86101066-A | Process for producing novel trifluoromethyl ketone substituted peptide derivatives | — | 1986-11-05 | — | — | CN | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | EGFR 1565/4885ERBB2 905/4885KDM4E 2175/4885 |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | EGFR 1656/4885ERBB2 880/4885KDM4E 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.